[HTML][HTML] Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy
H Zhang, SY Yoon, H Zhang, PM Dougherty - The Journal of Pain, 2012 - Elsevier
Paclitaxel often induces persistent painful neuropathy as its most common treatment-limiting
side effect. Little is known concerning the underlying mechanisms. Given the prominent role …
side effect. Little is known concerning the underlying mechanisms. Given the prominent role …
Paclitaxel‐induced neuropathic pain is age dependent and devolves on glial response
J Ruiz‐Medina, A Baulies, SA Bura… - European journal of …, 2013 - Wiley Online Library
Background Paclitaxel is an antimitotic antitumour drug highly effective against a broad
range of cancers considered refractory to conventional chemotherapy. One of the main …
range of cancers considered refractory to conventional chemotherapy. One of the main …
Pathomechanisms of paclitaxel-induced peripheral neuropathy
I Klein, HC Lehmann - Toxics, 2021 - mdpi.com
Peripheral neuropathy is one of the most common side effects of chemotherapy, affecting up
to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces …
to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces …
[HTML][HTML] Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity
SY Yoon, CR Robinson, H Zhang, PM Dougherty - The Journal of Pain, 2013 - Elsevier
Spinal glial cells contribute to the development of many types of inflammatory and
neuropathic pain. Here the contribution of spinal astrocytes and astrocyte gap junctions to …
neuropathic pain. Here the contribution of spinal astrocytes and astrocyte gap junctions to …
Paclitaxel-activated astrocytes produce mechanical allodynia in mice by releasing tumor necrosis factor-α and stromal-derived cell factor 1
Background Paclitaxel is a widely used and potent chemotherapeutic agent for the treatment
of cancer. However, patients receiving paclitaxel often develop an acute pain syndrome for …
of cancer. However, patients receiving paclitaxel often develop an acute pain syndrome for …
Interleukin‐1beta released by microglia initiates the enhanced glutamatergic activity in the spinal dorsal horn during paclitaxel‐associated acute pain syndrome
Patients receiving paclitaxel for cancer treatment often develop an acute pain syndrome
(paclitaxel‐associated acute pain syndrome, P‐APS), which occurs immediately after …
(paclitaxel‐associated acute pain syndrome, P‐APS), which occurs immediately after …
Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and …
CM Peters, JM Jimenez-Andrade, BM Jonas… - Experimental …, 2007 - Elsevier
Paclitaxel-induced peripheral neuropathy (PN) can be a significant problem for patients
receiving chemotherapeutic regimens for the treatment of breast, ovarian, and lung cancer …
receiving chemotherapeutic regimens for the treatment of breast, ovarian, and lung cancer …
Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous …
JM Jimenez-Andrade, CM Peters, NA Mejia… - Neuroscience …, 2006 - Elsevier
Paclitaxel-induced peripheral neuropathy is a sensory neuropathy that affects thousands of
cancer patients each year as paclitaxel is commonly used to treat breast, non-small cell lung …
cancer patients each year as paclitaxel is commonly used to treat breast, non-small cell lung …
An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat
CM Peters, JM Jimenez-Andrade, MA Kuskowski… - Brain research, 2007 - Elsevier
Paclitaxel (Taxol®) is a frontline antineoplastic agent used to treat a variety of solid tumors
including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a …
including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a …
Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats
A Ledeboer, BM Jekich, EM Sloane… - Brain, behavior, and …, 2007 - Elsevier
Paclitaxel is a commonly used cancer chemotherapy drug that frequently causes painful
peripheral neuropathies. The mechanisms underlying this dose-limiting side effect are …
peripheral neuropathies. The mechanisms underlying this dose-limiting side effect are …